{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T16:23:14Z","timestamp":1783527794488,"version":"3.55.0"},"reference-count":104,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: Overexpression of programmed death-ligand 1 (PD-L1) and programmed cell death protein 1 (PD-1) induces immune evasion by cancer cells. Nivolumab and pembrolizumab (anti-PD-1 antibodies) are used to treat advanced non-small cell lung cancer (NSCLC). However, objective response rates are limited (20\u201330%), indicating that individual tumor microenvironments may differ according to immune evasion processes. Therefore, the development of biomarkers predictive of responders to immune checkpoint inhibitors is necessary. Activation of the nuclear factor erythroid 2-related factor 2\/Kelch-like ECH-associated protein 1 (NRF2\/KEAP1) signaling pathway promotes lung cancer cell growth and resistance to chemotherapy, radiotherapy, targeted therapy, and PD-1\/PD-L1 inhibition. The present study investigated whether NRF2 expression in NSCLC is associated with clinicopathological factors, the expression levels of intratumoral PD-L1 and CD8, and the efficacy of anti-PD-1 monotherapy. Methods: NRF2, PD-L1, and CD8 expression on tumor cells and tumor-infiltrating lymphocytes were examined by immunohistochemistry in 54 patients with advanced adenocarcinoma (N = 40) and squamous cell carcinoma (N = 14) treated with nivolumab or pembrolizumab. Histological subtypes, tumor stages, and other clinicopathological features were compared with their expression levels. Results: Weak NRF2 staining was significantly correlated with high levels of PD-L1 and CD8+ tumor-infiltrating lymphocytes, and a favorable response to treatment with nivolumab or pembrolizumab in NSCLC. Progression-free survival of patients treated with anti-PD-1 therapy differed according to the different NRF2 levels. Conclusions: NRF2 overexpression in NSCLC is associated with resistance to PD-1 blockade monotherapy.<\/jats:p>","DOI":"10.3390\/cancers18142202","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T15:40:09Z","timestamp":1783525209000},"page":"2202","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Feasibility Study of Intratumoral NRF2 Expression as a Predictive Biomarker for the Effectiveness of Immunotherapy in Patients with Non-Small Cell Lung Cancer Treated with PD-1 Inhibitor"],"prefix":"10.3390","volume":"18","author":[{"given":"Yasuto","family":"Jin","sequence":"first","affiliation":[{"name":"Department of Respiratory Medicine, Hiratsuka Kyosai Hospital, 9-11 Oiwake, Hiratsuka 254-8502, Kanagawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-9878-5835","authenticated-orcid":false,"given":"Yukihisa","family":"Inoue","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Hiratsuka Kyosai Hospital, 9-11 Oiwake, Hiratsuka 254-8502, Kanagawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-1729-2966","authenticated-orcid":false,"given":"Hiroyuki","family":"Shimada","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Hiratsuka Kyosai Hospital, 9-11 Oiwake, Hiratsuka 254-8502, Kanagawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsu","family":"Hara","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Hiratsuka Kyosai Hospital, 9-11 Oiwake, Hiratsuka 254-8502, Kanagawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shohei","family":"Yamashita","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Hiratsuka Kyosai Hospital, 9-11 Oiwake, Hiratsuka 254-8502, Kanagawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mio","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Hiratsuka Kyosai Hospital, 9-11 Oiwake, Hiratsuka 254-8502, Kanagawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osamu","family":"Matsubara","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Pathology, Hiratsuka Kyosai Hospital, 9-11 Oiwake, Hiratsuka 254-8502, Kanagawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients","volume":"515","author":"Herbst","year":"2014","journal-title":"Nature"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1038\/ni.2762","article-title":"A rheostat for immune responses: The unique properties of PD-1 and their advantages for clinical application","volume":"14","author":"Okazaki","year":"2013","journal-title":"Nat. Immunol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1158\/2326-6066.CIR-15-0210","article-title":"PD-1 Blockade Expands Intratumoral Memory T Cells","volume":"4","author":"Ribas","year":"2016","journal-title":"Cancer Immunol. Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1158\/1078-0432.CCR-14-2959","article-title":"Immune Checkpoint Modulation for Non\u2013Small Cell Lung Cancer","volume":"21","author":"Soria","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jtho.2017.11.123","article-title":"Predictive Performance of Four Programmed Cell Death Ligand 1 Assay Systems on Nivolumab Response in Previously Treated Patients with Non\u2013Small Cell Lung Cancer","volume":"13","author":"Fujimoto","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","article-title":"Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: Prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study","volume":"21","author":"Marabelle","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/s41588-018-0312-8","article-title":"Tumor mutational load predicts survival after immunotherapy across multiple cancer types","volume":"51","author":"Samstein","year":"2019","journal-title":"Nat. Genet."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e963413","DOI":"10.4161\/21624011.2014.963413","article-title":"Unleashing the immune system: PD-1 and PD-Ls in the pre-treatment tumor microenvironment and correlation with response to PD-1\/PD-L1 blockade","volume":"3","author":"Taube","year":"2014","journal-title":"OncoImmunology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1200\/JCO.21.02885","article-title":"Five-year outcomes with pembrolizumab versus chemotherapy as first-line therapy in patients with non-small-cell lung cancer and programmed death ligand-1 tumor proportion score \u2265 1% in the KEYNOTE-042 study","volume":"41","author":"Kudaba","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/j.jtho.2021.03.017","article-title":"Predictors of Response, Progression-Free Survival, and Overall Survival in Patients with Lung Cancer Treated with Immune Checkpoint Inhibitors","volume":"16","author":"Memmott","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"7207","DOI":"10.1002\/cam4.2580","article-title":"The landscape of immune microenvironment in lung adenocarcinoma and squamous cell carcinoma based on PD-L1 expression and tumor-infiltrating lymphocytes","volume":"8","author":"Chen","year":"2019","journal-title":"Cancer Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1158\/1078-0432.CCR-15-2834","article-title":"Pan-cancer immunogenomic perspective on the tumor microenvironment based on PD-L1 and CD8 T-cell infiltration","volume":"22","author":"Ock","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Li, H., Sunder, S.S., Jatwani, K., Bae, Y., Deng, L., Liu, Q., Dy, G.K., and Pokharel, S. (2024). Tumor Characteristics and Treatment Responsiveness in Pembrolizumab-Treated Non-Small Cell Lung Carcinoma. Cancers, 16.","DOI":"10.3390\/cancers16040744"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"9999","DOI":"10.1073\/pnas.1822001116","article-title":"PD-1+ regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer","volume":"116","author":"Kamada","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1038\/s41590-020-0769-3","article-title":"The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies","volume":"21","author":"Kumagai","year":"2020","journal-title":"Nat. Immunol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/s41586-018-0130-2","article-title":"Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates","volume":"557","author":"Simoni","year":"2018","journal-title":"Nature"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.jtho.2017.11.132","article-title":"Stromal PD-L1\u2013Positive Regulatory T cells and PD-1\u2013Positive CD8-Positive T cells Define the Response of Different Subsets of Non\u2013Small Cell Lung Cancer to PD-1\/PD-L1 Blockade Immunotherapy","volume":"13","author":"Wu","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.cell.2006.05.036","article-title":"TIGAR, a p53-Inducible Regulator of Glycolysis and Apoptosis","volume":"126","author":"Bensaad","year":"2006","journal-title":"Cell"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.cell.2017.04.004","article-title":"Metabolic instruction of immunity","volume":"169","author":"Buck","year":"2017","journal-title":"Cell"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/s41577-019-0203-y","article-title":"Metabolic coordination of T cell quiescence and activation","volume":"20","author":"Chapman","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/s41568-020-0273-y","article-title":"Metabolism of immune cells in cancer","volume":"20","author":"Leone","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2340154","DOI":"10.1080\/2162402X.2024.2340154","article-title":"Redox high phenotype mediated by KEAP1\/STK11\/SMARCA4\/NRF2 mutations diminishes tissue-resident memory CD8+ T cells and attenuates the efficacy of immunotherapy in lung adenocarcinoma","volume":"13","author":"Wei","year":"2024","journal-title":"OncoImmunology"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e175897","DOI":"10.1172\/JCI175897","article-title":"Lactate supports Treg function and immune balance via MGAT1 effects on N-glycosylation in the mitochondria","volume":"134","author":"Zhou","year":"2024","journal-title":"J. Clin. Investig."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.tibs.2010.04.002","article-title":"Mitochondrial reactive oxygen species regulate cellular signaling and dictate biological outcomes","volume":"35","author":"Hamanaka","year":"2010","journal-title":"Trends Biochem. Sci."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1126\/science.1211485","article-title":"Inhibition of Pyruvate Kinase M2 by Reactive Oxygen Species Contributes to Cellular Antioxidant Responses","volume":"334","author":"Anastasiou","year":"2011","journal-title":"Science"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/1476-4598-12-138","article-title":"Ets-1 regulates intracellular glutathione levels: Key target for resistant ovarian cancer","volume":"12","author":"Verschoor","year":"2013","journal-title":"Mol. Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3812","DOI":"10.1182\/blood-2006-07-035972","article-title":"Inhibitory effect of tumor cell\u2013derived lactic acid on human T cells","volume":"109","author":"Fischer","year":"2007","journal-title":"Blood"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"6921","DOI":"10.1158\/0008-5472.CAN-11-1457","article-title":"Lactate: A Metabolic Key Player in Cancer","volume":"71","author":"Hirschhaeuser","year":"2011","journal-title":"Cancer Res."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Serganova, I., Cohen, I.J., Vemuri, K., Shindo, M., Maeda, M., Mane, M., Moroz, E., Khanin, R., Satagopan, J., and A Koutcher, J. (2018). LDH-A regulates the tumor microenvironment via HIF-signaling and modulates the immune response. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0203965"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.ygeno.2004.08.010","article-title":"Genes of glycolysis are ubiquitously overexpressed in 24 cancer classes","volume":"84","author":"Altenberg","year":"2004","journal-title":"Genomics"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.cell.2015.08.016","article-title":"Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression","volume":"162","author":"Chang","year":"2015","journal-title":"Cell"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.cell.2008.08.021","article-title":"Cancer Cell Metabolism: Warburg and Beyond","volume":"134","author":"Hsu","year":"2008","journal-title":"Cell"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrc3038","article-title":"Otto Warburg\u2019s contributions to current concepts of cancer metabolism","volume":"11","author":"Koppenol","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.cmet.2015.12.006","article-title":"The Emerging Hallmarks of Cancer Metabolism","volume":"23","author":"Pavlova","year":"2016","journal-title":"Cell Metab."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1101\/gad.13.1.76","article-title":"Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain","volume":"13","author":"Itoh","year":"1999","journal-title":"Genes Dev."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1128\/MCB.26.1.221-229.2006","article-title":"Oxidative and Electrophilic Stresses Activate Nrf2 through Inhibition of Ubiquitination Activity of Keap1","volume":"26","author":"Kobayashi","year":"2006","journal-title":"Mol. Cell. Biol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.bbamcr.2018.02.010","article-title":"Nrf2-Keap1 signaling in oxidative and reductive stress","volume":"1865","author":"Bellezza","year":"2018","journal-title":"Biochim. Biophys. Acta (BBA)-Mol. Cell Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1046\/j.1365-2443.2003.00640.x","article-title":"Keap1 regulates both cytoplasmic-nuclear shuttling and degradation of Nrf2 in response to electrophiles","volume":"8","author":"Itoh","year":"2003","journal-title":"Genes Cells"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Taguchi, K., and Yamamoto, M. (2017). The KEAP1\u2013NRF2 System in Cancer. Front. Oncol., 7.","DOI":"10.3389\/fonc.2017.00085"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.jtho.2022.03.011","article-title":"KEAP1-Mutant NSCLC: The Catastrophic Failure of a Cell-Protecting Hub","volume":"17","author":"Scalera","year":"2022","journal-title":"J. Thorac. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.annonc.2022.12.002","article-title":"Clonal KEAP1 mutations with loss of heterozygosity share reduced immunotherapy efficacy and low immune cell infiltration in lung adenocarcinoma","volume":"34","author":"Scalera","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.bbrc.2008.06.004","article-title":"Hypermethylation of the Keap1 gene in human lung cancer cell lines and lung cancer tissues","volume":"373","author":"Wang","year":"2008","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.bbrc.2012.10.010","article-title":"A possible gene silencing mechanism: Hypermethylation of the Keap1 promoter abrogates binding of the transcription factor Sp1 in lung cancer cells","volume":"428","author":"Guo","year":"2012","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_46","first-page":"1244","article-title":"Genetic and epigenetic regulation of the NRF2-KEAP1 pathway in human lung cancer","volume":"126","author":"Penning","year":"2021","journal-title":"Br. J. Cancer"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.jtho.2025.01.016","article-title":"Gene Copy Deletion of STK11, KEAP1, and SMARCA4: Clinicopathologic Features and Association with the Outcomes of Immunotherapy with or Without Chemotherapy in Nonsquamous NSCLC","volume":"20","author":"Gandhi","year":"2025","journal-title":"J. Thorac. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1016\/j.jtho.2019.07.003","article-title":"Mutations in the KEAP1-NFE2L2 Pathway Define a Molecular Subset of Rapidly Progressing Lung Adenocarcinoma","volume":"14","author":"Goeman","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jtho.2020.11.015","article-title":"Clinical Implications of KEAP1-NFE2L2 Mutations in NSCLC","volume":"16","author":"Hellyer","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.mam.2011.10.006","article-title":"Oxidative stress in health and disease: The therapeutic potential of Nrf2 activation","volume":"32","author":"Hybertson","year":"2011","journal-title":"Mol. Asp. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ccr.2012.05.016","article-title":"Nrf2 Redirects Glucose and Glutamine into Anabolic Pathways in Metabolic Reprogramming","volume":"22","author":"Mitsuishi","year":"2012","journal-title":"Cancer Cell"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"16889","DOI":"10.1038\/srep16889","article-title":"Nuclear factor, erythroid 2-like 2-associated molecular signature predicts lung cancer survival","volume":"5","author":"Qian","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ccell.2018.03.022","article-title":"NRF2 and the hallmarks of cancer","volume":"34","author":"Chapman","year":"2018","journal-title":"Cancer Cell"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"9095","DOI":"10.1158\/0008-5472.CAN-10-0384","article-title":"Global downstream pathway analysis reveals a dependence of oncogenic NF-E2-related factor 2 mutation on the mTOR growth signaling pathway","volume":"70","author":"Shibata","year":"2010","journal-title":"Cancer Res."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"7975","DOI":"10.1158\/0008-5472.CAN-08-1401","article-title":"RNAi-mediated silencing of nuclear factor erythroid-2-related factor 2 gene expression in non-small cell lung cancer inhibits tumor growth and increases efficacy of chemotherapy","volume":"68","author":"Singh","year":"2008","journal-title":"Cancer Res."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Singh, A., Misra, V., Thimmulappa, R.K., Lee, H., Ames, S., O Hoque, M., Herman, J.G., Baylin, S.B., Sidransky, D., and Gabrielson, E. (2006). Dysfunctional KEAP1\u2013NRF2 Interaction in Non-Small-Cell Lung Cancer. PLoS Med., 3.","DOI":"10.1371\/journal.pmed.0030420"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"3743","DOI":"10.1158\/1078-0432.CCR-09-3352","article-title":"Nrf2 and Keap1 abnormalities in non-small cell lung carcinoma and association with clinicopathologic features","volume":"16","author":"Solis","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1158\/1940-6207.CAPR-14-0329","article-title":"Metabolomic markers of altered nucleotide metabolism in early stage adenocarcinoma","volume":"8","author":"Wikoff","year":"2015","journal-title":"Cancer Prev. Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.tibs.2014.02.002","article-title":"The Nrf2 regulatory network provides an interface between redox and intermediary metabolism","volume":"39","author":"Hayes","year":"2014","journal-title":"Trends Biochem. Sci."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1089\/ars.2010.3219","article-title":"Gain of Nrf2 Function in Non-Small-Cell Lung Cancer Cells Confers Radioresistance","volume":"13","author":"Singh","year":"2010","journal-title":"Antioxid. Redox Signal."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Panda, H., Wen, H., Suzuki, M., and Yamamoto, M. (2022). Multifaceted Roles of the KEAP1\u2013NRF2 System in Cancer and Inflammatory Disease Milieu. Antioxidants, 11.","DOI":"10.3390\/antiox11030538"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"4034","DOI":"10.1111\/cas.16355","article-title":"Specific cancer types and prognosis in patients with variations in the KEAP1-NRF2 system: A retrospective cohort study","volume":"115","author":"Iwasaki","year":"2024","journal-title":"Cancer Sci."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.tibs.2008.12.008","article-title":"NRF2 and KEAP1 mutations: Permanent activation of an adaptive response in cancer","volume":"34","author":"Hayes","year":"2009","journal-title":"Trends Biochem. Sci."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1158\/1078-0432.CCR-17-3416","article-title":"Clinical and Pathological Characteristics of KEAP1- and NFE2L2-Mutated Non\u2013Small Cell Lung Carcinoma (NSCLC)","volume":"24","author":"Frank","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"4743","DOI":"10.1007\/s11033-011-1266-4","article-title":"Mutation of the Nrf2 gene in non-small cell lung cancer","volume":"39","author":"Hu","year":"2011","journal-title":"Mol. Biol. Rep."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1016\/j.jtho.2023.07.020","article-title":"STK11\/LKB1-Deficient Phenotype Rather Than Mutation Diminishes Immunotherapy Efficacy and Represents STING\/Type I Interferon\/CD8+ T-Cell Dysfunction in NSCLC","volume":"18","author":"Li","year":"2023","journal-title":"J. Thorac. Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/ng.3564","article-title":"Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas","volume":"48","author":"Campbell","year":"2016","journal-title":"Nat. Genet."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.arcmed.2020.08.004","article-title":"Molecular Pathology of Primary Non-small Cell Lung Cancer","volume":"51","author":"Suster","year":"2020","journal-title":"Arch. Med. Res."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.molcel.2009.04.029","article-title":"Direct Interaction between Nrf2 and p21Cip1\/WAF1 Upregulates the Nrf2-Mediated Antioxidant Response","volume":"34","author":"Chen","year":"2009","journal-title":"Mol. Cell"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1128\/MCB.01204-10","article-title":"SCF\/\u03b2-TrCP Promotes Glycogen Synthase Kinase 3-Dependent Degradation of the Nrf2 Transcription Factor in a Keap1-Independent Manner","volume":"31","author":"Rada","year":"2011","journal-title":"Mol. Cell. Biol."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Sun, Z., Huang, Z., and Zhang, D.D. (2009). Phosphorylation of Nrf2 at Multiple Sites by MAP Kinases Has a Limited Contribution in Modulating the Nrf2-Dependent Antioxidant Response. PLoS ONE, 4.","DOI":"10.1371\/journal.pone.0006588"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1167\/iovs.07-1099","article-title":"Essential Roles of the PI3 Kinase\/Akt Pathway in Regulating Nrf2-Dependent Antioxidant Functions in the RPE","volume":"49","author":"Wang","year":"2008","journal-title":"Investig. Opthalmol. Vis. Sci."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1016\/j.jtho.2023.07.016","article-title":"KEAP1\/NFE2L2 Pathway Signature Outperforms KEAP1\/NFE2L2 Mutation Status and Reveals Alternative Pathway-Activating Mutations in NSCLC","volume":"18","author":"Arolt","year":"2023","journal-title":"J. Thorac. Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1158\/1078-0432.CCR-19-3663","article-title":"Baseline Plasma Tumor Mutation Burden Predicts Response to Pembrolizumab-based Therapy in Patients with Metastatic Non\u2013Small Cell Lung Cancer","volume":"26","author":"Aggarwal","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.annonc.2023.01.011","article-title":"Associations of tissue tumor mutational burden and mutational status with clinical outcomes in KEYNOTE-042: Pembrolizumab versus chemotherapy for advanced PD-L1-positive NSCLC","volume":"34","author":"Mok","year":"2023","journal-title":"Ann. Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"e955","DOI":"10.1634\/theoncologist.2019-0885","article-title":"NFE2L2\/KEAP1 Mutations Correlate with Higher Tumor Mutational Burden Value\/PD-L1 Expression and Potentiate Improved Clinical Outcome with Immunotherapy","volume":"25","author":"Xu","year":"2020","journal-title":"Oncologist"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"113295","DOI":"10.1016\/j.celrep.2023.113295","article-title":"KEAP1 mutation in lung adenocarcinoma promotes immune evasion and immunotherapy resistance","volume":"42","author":"Zavitsanou","year":"2023","journal-title":"Cell Rep."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Zhu, H., Xie, D., Yu, Y., Yao, L., Xu, B., Huang, L., Wu, S., Li, F., Zheng, Y., and Liu, X. (2021). KEAP1\/NFE2L2 Mutations of Liquid Biopsy as Prognostic Biomarkers in Patients with Advanced Non-Small Cell Lung Cancer: Results From Two Multicenter, Randomized Clinical Trials. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.659200"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"101302","DOI":"10.1016\/j.xcrm.2023.101302","article-title":"Tumor-immune microenvironment and NRF2 associate with clinical efficacy of PD-1 blockade combined with chemotherapy in lung squamous cell carcinoma","volume":"4","author":"Duan","year":"2023","journal-title":"Cell Rep. Med."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1111\/cas.16065","article-title":"Patient survey on cancer genomic medicine in Japan under the national health insurance system","volume":"115","author":"Kage","year":"2024","journal-title":"Cancer Sci."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.18632\/oncotarget.19838","article-title":"The prognostic value of NRF2 in solid tumor patients: A meta-analysis","volume":"9","author":"Wang","year":"2017","journal-title":"Oncotarget"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1097\/JTO.0000000000000630","article-title":"The 2015 World Health Organization Classification of Lung Tumors: Impact of genetic, clinical and radiologic advances since the 2004 classification","volume":"10","author":"Travis","year":"2015","journal-title":"J. Thorac. Oncol."},{"key":"ref_83","first-page":"81","article-title":"Immunohistochemical expression of nuclear factor erythroid-2-related factor 2 and heme oxygenase 1 in normal bovine lung and bovine lung infected with Mannheimia haemolytica","volume":"79","author":"Moussa","year":"2015","journal-title":"Can. J. Vet. Res."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1093\/annonc\/mdy014","article-title":"Multicenter harmonization study for PD-L1 IHC testing in non-small-cell lung cancer","volume":"29","author":"Adam","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jtho.2016.11.2228","article-title":"PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project","volume":"12","author":"Hirsch","year":"2017","journal-title":"J. Thorac. Oncol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1016\/j.jtho.2016.08.146","article-title":"A Harmonization Study for the Use of 22C3 PD-L1 Immunohistochemical Staining on Ventana\u2019s Platform","volume":"11","author":"Neuman","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"e000498","DOI":"10.1136\/esmoopen-2019-000498","article-title":"Immune checkpoint inhibitor treatment in patients with oncogene-addicted non-small cell lung cancer (NSCLC): Summary of a multidisciplinary round-table discussion","volume":"4","author":"Berghoff","year":"2019","journal-title":"ESMO Open"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"17588359231225036","DOI":"10.1177\/17588359231225036","article-title":"Efficacy of immunotherapy in patients with oncogene-driven non-small-cell lung cancer: A systematic review and meta-analysis","volume":"16","author":"Chen","year":"2024","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1158\/1078-0432.CCR-19-1237","article-title":"Role of KEAP1\/NFE2L2 Mutations in the Chemotherapeutic Response of Patients with Non\u2013Small Cell Lung Cancer","volume":"26","author":"Jeong","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1200\/JCO.21.00174","article-title":"Five-Year Outcomes with Pembrolizumab Versus Chemotherapy for Metastatic Non\u2013Small-Cell Lung Cancer with PD-L1 Tumor Proportion Score \u2265 50%","volume":"39","author":"Reck","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1245\/s10434-014-3600-2","article-title":"Nrf2 is Useful for Predicting the Effect of Chemoradiation Therapy on Esophageal Squamous Cell Carcinoma","volume":"21","author":"Kawasaki","year":"2014","journal-title":"Ann. Surg. Oncol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"103819","DOI":"10.1016\/j.redox.2025.103819","article-title":"Cisplatin-induced genetic alterations in KEAP1 promote therapeutic resistance in head and neck squamous cell carcinoma","volume":"86","author":"Nakayama","year":"2025","journal-title":"Redox Biol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1038\/s41419-022-05126-8","article-title":"Genetic alterations of Keap1 confers chemotherapeutic resistance through functional activation of Nrf2 and Notch pathway in head and neck squamous cell carcinoma","volume":"13","author":"Islam","year":"2022","journal-title":"Cell Death Dis."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/j.jtho.2022.09.109","article-title":"Predictive Biomarkers for Immunotherapy in Lung Cancer: Perspective From the International Association for the Study of Lung Cancer Pathology Committee","volume":"17","author":"Schalper","year":"2022","journal-title":"J. Thorac. Oncol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s12964-022-00906-3","article-title":"An update of Nrf2 activators and inhibitors in cancer prevention\/promotion","volume":"20","author":"Pouremamali","year":"2022","journal-title":"Cell Commun. Signal."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1042\/BJ20111943","article-title":"Antioxidant and bioenergetic coupling between neurons and astrocytes","volume":"443","author":"Almeida","year":"2012","journal-title":"Biochem. J."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.cllc.2020.10.006","article-title":"Phase 1 Trial of MLN0128 (Sapanisertib) and CB-839 HCl (Telaglenastat) in Patients with Advanced NSCLC (NCI 10327): Rationale and Study Design","volume":"22","author":"Riess","year":"2020","journal-title":"Clin. Lung Cancer"},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Staurengo-Ferrari, L., Badaro-Garcia, S., Hohmann, M.S.N., Manchope, M.F., Zaninelli, T.H., Casagrande, R., and Verri, W.A. (2019). Contribution of Nrf2 Modulation to the Mechanism of Action of Analgesic and Anti-inflammatory Drugs in Pre-clinical and Clinical Stages. Front. Pharmacol., 9.","DOI":"10.3389\/fphar.2018.01536"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"3619","DOI":"10.1038\/onc.2015.447","article-title":"Glutaminolysis as a target for cancer therapy","volume":"35","author":"Jin","year":"2016","journal-title":"Oncogene"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/s12276-023-00971-9","article-title":"Targeting glutamine metabolism as a therapeutic strategy for cancer","volume":"55","author":"Jin","year":"2023","journal-title":"Exp. Mol. Med."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.1158\/0008-5472.CAN-18-3527","article-title":"LKB1 and KEAP1\/NRF2 Pathways Cooperatively Promote Metabolic Reprogramming with Enhanced Glutamine Dependence in KRAS-Mutant Lung Adenocarcinoma","volume":"79","author":"Sitthideatphaiboon","year":"2019","journal-title":"Cancer Res."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1038\/nm.4407","article-title":"Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis","volume":"23","author":"Romero","year":"2017","journal-title":"Nat. Med."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"3435","DOI":"10.1038\/s41467-026-71608-4","article-title":"Differential KEAP1\/NRF2 mediated signaling widens the therapeutic window of redox-targeting drugs in SCLC therapy","volume":"17","author":"Samarin","year":"2026","journal-title":"Nat. Commun."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"3331","DOI":"10.1158\/0008-5472.CAN-19-2888","article-title":"Microenvironmental Activation of Nrf2 Restricts the Progression of Nrf2-Activated Malignant Tumors","volume":"80","author":"Hayashi","year":"2020","journal-title":"Cancer Res."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/14\/2202\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T15:55:28Z","timestamp":1783526128000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/14\/2202"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,8]]},"references-count":104,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["cancers18142202"],"URL":"https:\/\/doi.org\/10.3390\/cancers18142202","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,8]]}}}